{"createdAt":"8/2/2020, 2:35:07 PM","timestamp":1596393307706,"Company ID number":"628","DMX_ISSUER_NAME":"JIANGSU HENGRUI MEDICINE CO.,LTD.","DMX_ISSUER_ID":"IID000000002135147","Country of Classification":"CHINA","name":"Jiangsu Hengrui Medicine Co Ltd ","code":"600276","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"江苏恒瑞医药股份有限公司_周云曙","group":"board","name":"周云曙","title":"董事长,董事","isMale":true,"age":"49","degree":"博士","salary":"400.0万","stockAmount":"406.7万","description":"周云曙,男,1971年生,高级工程师、博士。1995年毕业于中国药科大学,1995年至今在江苏恒瑞医药股份有限公司工作,历任发展部副部长、副总经理、总经理、董事。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_戴洪斌","group":"board","name":"戴洪斌","title":"董事","isMale":true,"age":"44","degree":"硕士","salary":"112.0万","stockAmount":"131.6万","description":"戴洪斌,男,1976年生,2000年毕业于中南财经政法大学,获法学学士和经济学学士学位。2008年至2011年就读于武汉大学,获管理学硕士学位。2000年7月至今在江苏恒瑞医药股份有限公司工作,历任办公室主任和董事会秘书,2013年4月起任公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_孙杰平","group":"board","name":"孙杰平","title":"董事","isMale":true,"age":"50","degree":"硕士","salary":"134.0万","stockAmount":"150.1万","description":"孙杰平,男,1970年生,研究生学历,正高级会计师。1992年毕业于天津商学院会计学专业,1992年至1997年在连云港医药站工作,历任主管会计、财务经理、审计部经理等职,1998年任江苏恒瑞医药股份有限公司财务总监,2013年4月起任公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_张连山","group":"board","name":"张连山","title":"董事","isMale":true,"age":"59","degree":"博士","salary":"190.0万","stockAmount":"33.7万","description":"张连山,男,1961年生,美国国籍,1982年毕业于中国药科大学,1986年至1992年就读于德国蒂宾根大学,获有机化学博士学位;1992年1月至1994年6月在德国蒂宾根大学有机化学研究所工作,任研究助理;1994年7月至1998年2月在美国田纳西州纳什维尔市范德比尔特大学微生物学与免疫学系,任博士后研究员;1998年3月至2008年7月,在美国礼来工作,曾担任多个研究项目的高级化学家、首席研究科学家以及研究顾问等职务;2008年7月至2010年4月担任美国MarcadiaBiotech公司的高级化学总监,2010年8月起担任江苏恒瑞医药股份有限公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_孙飘扬","group":"board","name":"孙飘扬","title":"董事","isMale":true,"age":"62","degree":"博士","salary":"198.0万","stockAmount":"-","description":"孙飘扬,男,1958年生,研究员级高级工程师、博士,1982年毕业于中国药科大学化学制药专业,1997年至今任江苏恒瑞医药股份有限公司董事长,第十一、十二、十三届全国人大代表,国家药典委员会执行委员,享受国务院特殊津贴。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_郭丛照","group":"board","name":"郭丛照","title":"董事","isMale":false,"age":"48","degree":"硕士","salary":"0.00","stockAmount":"-","description":"郭丛照,女,汉族,1972年生,中共党员,硕士研究生学历。1996年8月至1998年9月历任财政部工交司中央工业二处干部、副主任科员,其间1996年10月至1997年9月在河北省平泉县财政局下派锻炼。1998年9月至2001年8月历任财政部经贸司制度处、企业司工业处主任科员。2001年8月至2014年8月历任财政部企业司企业一处主任科员、副处长、调研员、处长,其间2006年5月至2007年4月在天津市汉沽区人民政府挂职任区政府办副主任。2014年8月至2017年9月历任财政部资产管理司正处长级干部、国有企业改革处处长。2017年9月至2019年9月历任中国医药投资有限公司股权投资部总经理、投资总监,2019年9月至今任中国医药投资有限公司投资总监兼产业发展部总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_李援朝","group":"board","name":"李援朝","title":"独立董事","isMale":true,"age":"69","degree":"博士","salary":"6.000万","stockAmount":"-","description":"李援朝,男,1951年生,博士后,现任中国科学院上海药物研究所研究员,药物化学合成研究室主任,研究课题组组长,博士研究生导师。曾就职于福建省医药研究所、福建省医学科学研究所。2015年4月起任公司独立董事。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_王迁","group":"board","name":"王迁","title":"独立董事","isMale":true,"age":"45","degree":"博士","salary":"6.000万","stockAmount":"-","description":"王迁,男,1975年生,中共党员,博士,华东政法大学教授。1994年进入西北大学学习,2000年获法学硕士学位,同年进入北京大学学习,2003年获得法学博士学位。2003年7月至今,在华东政法大学工作,主要从事知识产权法研究。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_薛爽","group":"board","name":"薛爽","title":"独立董事","isMale":false,"age":"49","degree":"博士","salary":"6.000万","stockAmount":"-","description":"薛爽,女,1971年生,中共党员,博士,上海财经大学教授。1989年进入哈尔滨工业大学学习,1993年获学士学位,1993年至1996年在东北财经大学学习获硕士学位,1999年至2003年在清华大学学习获会计学博士学位。2003年至今,在上海财经大学会计学院工作,任会计学院院长助理。2007年至2008年作为访问学者,美国加州大学伯克利分校学习、工作。2014年起在上海紫江企业集团股份有限公司、风神股份有限公司、上海机电股份有限公司和江苏金融租赁股份有限公司等兼职工作。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_董伟","group":"supervisoryCommittee","name":"董伟","title":"监事会主席","isMale":true,"age":"49","degree":"本科","salary":"50.04万","stockAmount":"-","description":"董伟,男,1971年生,1993年毕业于中国药科大学化学合成专业。1993年至1995年在连云港制药厂工作,1995年9月至2002年4月在天津铭盛国际贸易有限公司工作,2002年至今为连云港恒创医药科技有限公司董事长,2003年以来为恒瑞医药监事会主席。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_熊国强","group":"supervisoryCommittee","name":"熊国强","title":"监事","isMale":true,"age":"45","degree":"本科","salary":"38.01万","stockAmount":"-","description":"熊国强,男,1975年生,1998年毕业于兰州商学院审计专业,1998至2001年恒瑞公司销售公司会计,2000至2002年成都恒瑞财务部工作,2002至2005年上海恒瑞财务部工作,2005年至2017年任江苏恒瑞医药股份有限公司审计部部长,2017年至今任江苏恒瑞医药股份有限公司政策事务部副总监。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_李佩晨","group":"supervisoryCommittee","name":"李佩晨","title":"职工监事","isMale":true,"age":"34","degree":"硕士","salary":"29.50万","stockAmount":"-","description":"李佩晨,男,1986年生,注册会计师,高级会计师,2010年毕业于南京理工大学经济管理学院会计学硕士。2010年7月至今在江苏恒瑞医药股份有限公司工作,现任内控管理部部长。","lastUpdated":"2019-12-31"},{"id":"江苏恒瑞医药股份有限公司_周云曙","group":"manager","name":"周云曙","title":"总经理","isMale":true,"age":"49","degree":"博士","salary":"400.0万","stockAmount":"406.7万","description":"周云曙,男,1971年生,高级工程师、博士。1995年毕业于中国药科大学,1995年至今在江苏恒瑞医药股份有限公司工作,历任发展部副部长、副总经理、总经理、董事。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_刘笑含","group":"manager","name":"刘笑含","title":"董事会秘书","isMale":false,"age":"35","degree":"硕士","salary":"36.51万","stockAmount":"8.52万","description":"刘笑含,女,1985年生,2011年毕业于华东政法大学,获法学硕士学位,获得国家法律职业资格证书。2011年8月至今在江苏恒瑞医药股份有限公司工作,历任证券法务部职员、副部长。2012年9月获得上海证券交易所董事会秘书任职资格,2013年起任江苏恒瑞医药股份有限公司证券事务代表,2016年6月起任江苏恒瑞医药股份有限公司董事会秘书。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_戴洪斌","group":"manager","name":"戴洪斌","title":"副总经理","isMale":true,"age":"44","degree":"硕士","salary":"112.0万","stockAmount":"131.6万","description":"戴洪斌,男,1976年生,2000年毕业于中南财经政法大学,获法学学士和经济学学士学位。2008年至2011年就读于武汉大学,获管理学硕士学位。2000年7月至今在江苏恒瑞医药股份有限公司工作,历任办公室主任和董事会秘书,2013年4月起任公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_孙杰平","group":"manager","name":"孙杰平","title":"副总经理","isMale":true,"age":"50","degree":"硕士","salary":"134.0万","stockAmount":"150.1万","description":"孙杰平,男,1970年生,研究生学历,正高级会计师。1992年毕业于天津商学院会计学专业,1992年至1997年在连云港医药站工作,历任主管会计、财务经理、审计部经理等职,1998年任江苏恒瑞医药股份有限公司财务总监,2013年4月起任公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_张连山","group":"manager","name":"张连山","title":"副总经理","isMale":true,"age":"59","degree":"博士","salary":"190.0万","stockAmount":"33.7万","description":"张连山,男,1961年生,美国国籍,1982年毕业于中国药科大学,1986年至1992年就读于德国蒂宾根大学,获有机化学博士学位;1992年1月至1994年6月在德国蒂宾根大学有机化学研究所工作,任研究助理;1994年7月至1998年2月在美国田纳西州纳什维尔市范德比尔特大学微生物学与免疫学系,任博士后研究员;1998年3月至2008年7月,在美国礼来工作,曾担任多个研究项目的高级化学家、首席研究科学家以及研究顾问等职务;2008年7月至2010年4月担任美国MarcadiaBiotech公司的高级化学总监,2010年8月起担任江苏恒瑞医药股份有限公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_蒋素梅","group":"manager","name":"蒋素梅","title":"副总经理","isMale":false,"age":"57","degree":"本科","salary":"171.0万","stockAmount":"115.5万","description":"蒋素梅,女,1963年11月生,1985毕业于中国药科大学,1985年9月至今在江苏恒瑞医药股份有限公司工作,曾任质检部部长、质量总监、副总经理,2014年3月起任江苏恒瑞医药股份有限公司常务副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_袁开红","group":"manager","name":"袁开红","title":"副总经理","isMale":true,"age":"55","degree":"本科","salary":"118.0万","stockAmount":"141.6万","description":"袁开红,男,1965年生,执业药师、高级工程师,1987年毕业于中国药科大学药学专业,学士学位,1987年8月至今,一直在江苏恒瑞医药股份有限公司工作,先后从事车间管理、药物制剂研究、药品注册和销售、药理研究管理、研发管理、药品注册和知识产权管理等工作,历任车间副主任、研究所副所长、发展部副部长、销售经理、副总工程师等职务,现任江苏恒瑞医药股份有限公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_沈亚平","group":"manager","name":"沈亚平","title":"副总经理","isMale":true,"age":"58","degree":"博士","salary":"158.1万","stockAmount":"26.96万","description":"沈亚平,男,1962年生,1984年毕业于广州暨南大学,1987年至1993年就读于加拿大渥太华大学,获有机化学博士学位。曾担任加拿大InflazymePharmaceuticalsLtd公司医药化学和工艺总监,LipontPharmaceuticalsInc公司总经理,美国ChemwerthInc公司中国区总经理。2012年4月加入恒瑞医药,担任董事长助理,2013年4月起任公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_孙绪根","group":"manager","name":"孙绪根","title":"副总经理","isMale":true,"age":"52","degree":"硕士","salary":"305.0万","stockAmount":"109.1万","description":"孙绪根先生个人简历,1968年4月24日生,1988-1993年就读于南通大学医学院临床医学系;2002-2005就读上海交通大学EMBA;1993年-1994年,在江苏盐务局总医院担任住院医师;1994年-1996年,在三九集团南方药厂担任医药代表、主管;1996年-2001年,在江苏正大天晴医药股份有限公司历任主管、办事处经理、大区经理、销售部经理、总监、总裁助理;2001年-2002年,在江苏正大天晴医药股份有限公司组建新药销售公司;2002年-2004年,在南京正大天晴医药公司担任营销副总经理,负责正大天晴新药营销;2005年1月至今,在恒瑞医药子公司新晨医药有限公司担任总经理;2013年8月起任江苏恒瑞医药股份有限公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_邹建军","group":"manager","name":"邹建军","title":"副总经理","isMale":false,"age":"49","degree":"博士","salary":"197.0万","stockAmount":"20.66万","description":"邹建军,女,1971年生,1989年进入第四军医大学临床医学系学习,1995毕业获得临床医学学士学位,1995年至2005年分别在解放军301医院临床医学部肿瘤科和上海长征医院肿瘤科任住院医生及主治医生,2005年8月获得第二军医大学临床肿瘤学博士学位。2005年10月至2012年在德国拜耳医药历任中国肿瘤研发部医学经理、治疗领域负责人、全球医学事务负责人(美国总部新泽西)。2012年10月在美国新基医药任医学总监、中国医学事务负责人。2015年9月底加入江苏恒瑞医药股份有限公司,任肿瘤临床副总经理。2017年6月至今在江苏恒瑞医药股份有限公司任副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_张月红","group":"manager","name":"张月红","title":"副总经理","isMale":false,"age":"45","degree":"硕士","salary":"147.0万","stockAmount":"-","description":"张月红,女,1975年生,1997年毕业于武汉科技大学流体传动与控制专业,获学士学位;1999年-2003年就读于北京首都经济贸易大学人力资源管理专业,获硕士学位;2017年-2018年就读于IMD瑞士洛桑国际管理学院,获高级管理人员工商管理硕士;1998年3月-2000年12月在兴运实业有限公司任人力资源和行政经理、主管;2001年1月-2003年1月在LG电子(中国)技术服务中心任人力资源和行政经理;2003年6月-2011年3月在北京诺华制药有限公司任人力资源及行政总监;2011年4月-2013年4月在山德士中国制药有限公司任人力资源总监;2013年5月-2015年10月在诺华美国加州制药工厂任人力资源总监;2015年11月-2018年7月在诺华瑞士总部任全球人力资源总监;2018年12月至今在江苏恒瑞医药股份有限公司任首席人力资源官。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_陶维康","group":"manager","name":"陶维康","title":"副总经理","isMale":true,"age":"57","degree":"博士","salary":"203.0万","stockAmount":"28.42万","description":"陶维康,国家“千人计划”专家,上海市“千人计划”专家,细胞生物学家和药理学家。现任上海恒瑞医药股份有限公司副总经理、研发中心CEO,负责创新药研发工作(临床前)以及上海研发中心、美国新泽西研发团队和上海抗体研究所的管理。毕业于第二军医大学医学系,后赴美国新泽西医科大学获得分子与细胞生物学博士学位,并在普林斯顿大学完成博士后研究。曾在美国Merck制药公司从事新药研发十多年,任资深研究员和部门主管,主持过多个抗癌新药的研发和项目管理。2015年7月起任江苏恒瑞医药股份有限公司副总经理。","lastUpdated":"2020-01-17"},{"id":"江苏恒瑞医药股份有限公司_王洪森","group":"manager","name":"王洪森","title":"副总经理","isMale":true,"age":"50","degree":"","salary":"--","stockAmount":"--","description":"王洪森,男,1970年生,1991年7月毕业于福州大学化学系物理化学专业。1991年8月至今在恒瑞医药工作,1991年8月至1994年12月任公司研究所及车间技术员,1995年1月至2009年12月历任物资供应部部长、总监,2010年1月至2015年9月任原料药分公司总监,2015年10月至今任江苏恒瑞医药股份有限公司生产副总经理。","lastUpdated":"2020-08-01"},{"id":"江苏恒瑞医药股份有限公司_周宋","group":"manager","name":"周宋","title":"财务总监","isMale":true,"age":"47","degree":"硕士","salary":"64.51万","stockAmount":"28.31万","description":"周宋,男,1973年生。1993年毕业于南京审计学院审计专业;2009年-2012年在南京理工大学攻读EMBA并获得硕士学位;1993-2002年在连云港市医药采购供应站工作,历任审计科副科长、财务部经理、总经理助理;2003年至今在江苏恒瑞医药股份有限公司工作,历任财务部副经理、财务部经理、研究院副院长,2014年4月起任公司财务总监。","lastUpdated":"2020-01-17"}],"companyName":"江苏恒瑞医药股份有限公司","province":"江苏省","englishName":"Jiangsu Hengrui Medicine Co Ltd","industry":"医药生物 — 化学制药","website":"www.hrs.com.cn","mainBusiness":"药品研发、生产和销售","productsName":["厄贝沙坦片","艾瑞昔布片","多西他赛注射液","碘克沙醇注射液","钠钾镁钙葡萄糖注射液","酒石酸布托啡诺注射液","注射用顺苯磺酸阿曲库铵","注射用紫杉醇(白蛋白结合型)"],"actualController":"孙飘扬","actualControllerSharePercentage":"22.40%","registeredCapital":"53.07亿元","employeeAmount":"24431","phone":"86-0518-81220983","location":"江苏省连云港市连云区经济技术开发区昆仑山路7号","chineseDescription":"江苏恒瑞医药股份有限公司是一家从事医药工业的公司,其主要生产产品包括了片剂、针剂、胶囊、粉针等制剂.\n　　公司是国内最大的抗肿瘤药、手术用药和造影剂的研究和生产基地之一。公司产品涵盖了抗肿瘤药、手术麻醉类用药、特色输液、造影剂、心血管药等众多领域，已形成比较完善的产品布局，其中抗肿瘤、手术麻醉、造影剂等领域市场份额在行业内名列前茅。报告期内，公司获得由中国化学制药工业协颁发的“2018中国化学制药行业工业企业综合实力百强”、“2018中国化学制药行业创新型优秀企业品牌”等众多荣誉。报告期内，公司作为国内医药创新和高质量发展的代表企业，荣获“全国五一劳动奖状”，并在中国化学制药行业年度峰会中荣获...查看全部▼江苏恒瑞医药股份有限公司是一家从事医药工业的公司,其主要生产产品包括了片剂、针剂、胶囊、粉针等制剂.\n　　公司是国内最大的抗肿瘤药、手术用药和造影剂的研究和生产基地之一。公司产品涵盖了抗肿瘤药、手术麻醉类用药、特色输液、造影剂、心血管药等众多领域，已形成比较完善的产品布局，其中抗肿瘤、手术麻醉、造影剂等领域市场份额在行业内名列前茅。报告期内，公司获得由中国化学制药工业协颁发的“2018中国化学制药行业工业企业综合实力百强”、“2018中国化学制药行业创新型优秀企业品牌”等众多荣誉。报告期内，公司作为国内医药创新和高质量发展的代表企业，荣获“全国五一劳动奖状”，并在中国化学制药行业年度峰会中荣获“2019中国化学制药行业工业企业综合实力百强”、“2019中国化学制药行业创新型优秀企业品牌”等众多荣誉。收起▲","foundedDate":"1997-04-28","goPublicDate":"2000-10-18","companyHistory":"江苏恒瑞医药股份有限公司（以下简称“公司”）是1997年2月经江苏省人民政府苏政复[1997]19号文件批准设立，由连云港恒瑞集团有限公司（原连云港市医药工业公司）、中国医药工业公司等五家发起人共同发起设立的股份有限公司。公司于1997年4月28日登记注册,并领取了连云港市工商行政管理局核发的营业执照，统一社会信用代码为9132070070404786XB。公司住所为连云港经济技术开发区黄河路38号，法定代表人：孙飘扬。\n　　公司设立时的注册资本为6,190.00万元人民币；1999年5月，以未分配利润按每10股送5股分配股票股利3,095.00万元，注册资本及股本增加至9,285.00万元；经中国证券监督管理委员会证监发行字[2000]122号文批准，2000年9月通过上海证券交易所向社会公众发行人民币普通股4000万股，股票每股面值为人民币1元，发行后的股本总额为13,285.00万元，同年10月，在上海证券交易所挂牌上市,股票代码为600276。\n　　截止2016年6月30日，公司股份总额为234,776.2891万股。\n　　截止2017年6月30日，公司股份总额为281,688.9833万股。\n　　截至2017年12月31日，公司股份总额为283,264.8038万股。\n　　截止2018年6月30日，公司股份总额为368,244.2449万股。\n截止2018年12月31日,公司注册资本为368,244.2449万元人民币,实收股份总额为368,586.2057万股,尚未变更注册资本。\n　　截止2019年6月30日，公司注册资本为442,281.4196万元人民币，实收股份总额为442,281.4197万股，尚未变更注册资本。\n　　截止2019年12月31日，公司注册资本为442,281.4196万元人民币。收起▲","shareholders":[{"organizationId":"03148257","holderName":"江苏恒瑞医药集团有限公司","totalShare":"10.68亿","sharePercentage":"24.15%"},{"organizationId":"T000157443","holderName":"西藏达远企业管理有限公司","totalShare":"6.62亿","sharePercentage":"14.96%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"5.25亿","sharePercentage":"11.86%"},{"organizationId":"00069182","holderName":"连云港恒创医药科技有限公司","totalShare":"2.15亿","sharePercentage":"4.87%"},{"organizationId":"T003855553","holderName":"中国医药投资有限公司","totalShare":"1.85亿","sharePercentage":"4.19%"},{"organizationId":"T000366199","holderName":"连云港市金融控股集团有限公司","totalShare":"1.49亿","sharePercentage":"3.37%"},{"organizationId":"Q014B35FDE","holderName":"上海有沃科技有限公司","totalShare":"1.13亿","sharePercentage":"2.54%"},{"organizationId":"","holderName":"奥本海默基金公司-中国基金","totalShare":"7869.53万","sharePercentage":"1.78%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"6625.00万","sharePercentage":"1.50%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"4105.48万","sharePercentage":"0.93%"}],"englishDescription":"JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"88.18","Price to sales (ttm)":"21.00","Price to book (mrq)":"19.10","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"0.00","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"23.26","Return on equity (ttm)":"20.78","Income statement":{"Revenue":"23,288.58","Total revenue":"23,288.58","Cost of revenue, total":"2,918.42","Gross profit":"20,370.16","Selling/general/admin. expenses, total":"10,959.35","Research & development":"3,660.51","Depreciation/amortization":"272.19","Interest exp.(inc.),net-operating, total":"(478.60)","Unusual expense (income)":"(1.24)","Other operating expenses, total":"(191.74)","Total operating expense":"17,138.90","Operating income":"6,149.68","Gain (loss) on sale of assets":"(1.67)","Other, net":"(92.25)","Net income before taxes":"6,055.76","Provision for income taxes":"729.31","Net income after taxes":"5,326.45","Minority interest":"1.58","Net income before extra. items":"5,328.03","Net income":"5,328.03","Income available to com excl extraord":"5,328.03","Income available to com incl extraord":"5,328.03","Diluted net income":"5,328.03","Diluted weighted average shares":"5,307.40","Diluted eps excluding extraord items":"1.00","Dps - common stock primary issue":"0.19","Diluted normalized eps":"1.00"},"Balance sheet":{"Cash":"0.05","Cash & equivalents":"5,030.87","Short term investments":"8,607.48","Cash and short term investments":"13,638.39","Accounts receivable - trade, net":"4,906.25","Total receivables, net":"6,462.21","Total inventory":"1,606.81","Prepaid expenses":"591.16","Other current assets, total":"12.73","Total current assets":"22,311.30","Property/plant/equipment, total - gross":"6,648.33","Accumulated depreciation, total":"(2,573.53)","Property/plant/equipment, total - net":"4,074.80","Intangibles, net":"349.76","Long term investments":"599.43","Other long term assets, total":"221.18","Total assets":"27,556.48","Accounts payable":"1,289.25","Accrued expenses":"185.23","Notes payable/short term debt":"315.18","Other current liabilities, total":"682.98","Total current liabilities":"2,472.63","Total long term debt":"0.00","Total debt":"315.18","Deferred income tax":"24.09","Minority interest":"162.20","Other liabilities, total":"122.22","Total liabilities":"2,781.15","Common stock, total":"4,422.81","Additional paid-in capital":"1,662.97","Retained earnings (accumulated deficit)":"19,102.85","Treasury stock - common":"(419.84)","Other equity, total":"6.53","Total equity":"24,775.32","Total liabilities & shareholders' equity":"27,556.48","Total common shares outstanding":"5,284.70","Tangible book value per share, common eq":"4.62","Long term debt":"0.00","Current port. of  lt debt/capital leases":"10.03"},"Cash flow":{"Cash receipts":"23,279.84","Cash payments":"(1,085.05)","Cash taxes paid":"(2,428.24)","Changes in working capital":"(15,949.73)","Cash from operating activities":"3,816.83","Capital expenditures":"(561.35)","Other investing cash flow items, total":"(1,384.09)","Cash from investing activities":"(1,945.44)","Financing cash flow items":"92.38","Total cash dividends paid":"(810.89)","Cash from financing activities":"(718.51)","Foreign exchange effects":"12.31","Net change in cash":"1,165.19","Issuance (retirement) of debt, net":"(10.00)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"94.38","52 Week High":"105.00","52 Week Low":"51.54","Pricing date":"","10 Day Average Trading Volume":"33.06","Market Capitalization":"500,851.10","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"609.31","Beta":"0.64","1 Day Price Change":"-0.62","13 Week Price Return (Daily)":"21.78","26 Week Price Return (Daily)":"28.71","5 Day Price Return (Daily)":"-0.43","52 Week Price Return (Daily)":"69.72","Year To Date Price Return (Daily)":"29.41","Month to Date Price Return (Daily)":"2.25","Price Relative to S&P500 (4 Week)":"-2.16","Price Relative to S&P500 (13 Week)":"5.23","Price Relative to S&P500 (26 Week)":"15.75","Price Relative to S&P500 (52 Week)":"49.15","Price Relative to S&P500 (YTD)":"19.25"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"1.00","EPS excl. Extra Items (TTM)":"1.07","EPS Normalized (Annual)":"1.00","Revenue per Share (Annual)":"4.39","Revenue per Share (TTM)":"4.66","Book Value (Per Share Annual)":"4.69","Book Value (Per Share Quarterly)":"4.94","Tangible Book Value (Per Share Annual)":"4.62","Tangible Book Value (Per Share Quarterly)":"4.88","Cash Per Share (Per Share Annual)":"2.58","Cash Per Share (Per Share Quarterly)":"2.84","Cash Flow (Per Share Annual)":"1.12","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.19","Dividends (Per Share TTM)":"0.19","EBITD (Per Share TTM)":"1.14","EPS Basic excl. Extra Items (Annual)":"1.00","EPS Basic excl. Extra Items (TTM)":"1.07","EPS incl. Extra Items (Annual)":"1.00","EPS incl. Extra Items (TTM)":"1.07","Free Cash Flow (Per Share TTM)":"0.78","Dividend (Per Share 5Y)":"0.10"},"Valuation":{"P/E excl. Extra Items (Annual)":"94.01","P/E excl. Extra Items (TTM)":"88.18","P/E Normalized (Annual)":"94.01","Price to sales (Annual)":"21.51","Price to sales (TTM)":"21.00","Price to Tangible Book (Annual)":"20.51","Price to Tangible Book (Quarterly)":"19.44","Price to Free Cash Flow (Per Share Annual)":"204.88","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"126.21","Price to Book (Annual)":"20.13","Price to Book (Quarterly)":"19.10","P/E Basic excl. Extra Items (TTM)":"71.65","P/E excl. Extra Items High (TTM)":"78.03","P/E excl. Extra Items Low (TTM)":"36.88","P/E incl. Extra Items (TTM)":"88.18","Net Debt (Interim)":"-15,005.80","Net Debt (Annual)":"-13,323.21","Dividend Yield (5Y)":"0.28","Dividend Yield":"0.20","Current Dividend Yield (TTM)":"0.20"},"Financial Strength":{"Free Cash Flow (Annual)":"2,444.59","Current Ratio (Annual)":"9.02","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"19.09","Quick Ratio (Annual)":"8.37","Total Debt/Total Equity (Annual)":"1.27","Current EV/Free Cash Flow (Annual)":"106.65","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"8.69","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"8.05","Total Debt/Total Equity (Quarterly)":"0.00","Free Cash Flow (TTM)":"3,968.34","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"18.66"},"Margins":{"Gross Margin (Annual)":"87.47","Gross Margin (TTM)":"86.59","Net Profit Margin % (Annual)":"22.87","Net Profit Margin (TTM)":"22.80","Operating Margin (Annual)":"26.41","Operating Margin (TTM)":"26.66","Pretax Margin (TTM)":"26.21","Pretax Margin (Annual)":"26.00","Operating Margin (5Y)":"26.87","Pretax Margin (5Y)":"26.54","Free Operating Cash Flow/Revenue (5Y)":"12.26","Free Operating Cash Flow/Revenue (TTM)":"16.64","Gross Margin (5Y)":"86.78","Net Profit Margin (5Y)":"23.40"},"Management Effectiveness":{"Return on Assets (Annual)":"21.34","Return on Equity (TTM)":"20.78","Return on Average Equity (Annual)":"23.94","Return on Average equity (TTM)":"23.42","Return on Investment (Annual)":"23.82","Return on Investment (TTM)":"23.26","Return on Average Assets (5Y)":"20.74","Return on Average Equity (5Y)":"23.57","Return on Investment (5Y)":"23.67","Asset Turnover (Annual)":"0.93","Asset Turnover (TTM)":"0.91","Inventory Turnover (Annual)":"2.21","Inventory Turnover (TTM)":"2.17","Net Income/Employee (Annual)":"234,402.80","Net Income/Employee (TTM)":"222,608.20","Receivables Turnover (Annual)":"5.37","Receivables Turnover (TTM)":"5.66","Revenue/Employee (Annual)":"1,024,868.00","Revenue/Employee (TTM)":"976,167.10"},"Growth":{"Revenue Growth (Quarterly YoY)":"11.28","Revenue Growth Rate (5Y)":"25.59","EPS Growth (Quarterly YoY)":"29.07","EPS Growth (TTM YoY)":"31.23","EPS Growth Rate (5Y)":"28.43","Dividend Growth Rate (3Y)":"47.20","Revenue Growth (TTM YoY)":"28.72","Revenue Growth (Per Share 5Y)":"25.44","Revenue Growth Rate (3Y)":"28.04","EPS Growth Rate (3Y)":"26.85","Book Value Growth Rate (Per Share 5Y)":"19.38","Tangible Book Value Total Equity CAGR (5Y)":"26.31","Capital Spending growth rate 5 year":"13.46","EBITDA CAGR (5Y)":"26.99","EBITDA Interim CAGR (5Y)":"25.52","Free Operating Cash Flow CAGR (5Y)":"16.21","Total Debt CAGR (5Y)":"57.11","Net Profit Margin Growth Rate (5Y)":"1.62"},"Income Statement":{"Revenue (Annual)":"23,288.58","Revenue (TTM)":"23,848.74","EBITD (Annual)":"6,288.36","EBITD (TTM)":"5,813.16","Earnings Before Taxes (Annual)":"6,055.76","Earnings Before Taxes (TTM)":"6,249.87","Net Income to Common (Annual)":"5,328.03","Net Income to Common (TTM)":"5,450.85","Earnings Before Taxes Normalized (Annual)":"6,056.19","Net Income Available to Common Normalized (Annual)":"5,328.41","Diluted Normalized EPS excl. Extra Items (TTM)":"1.07"}}}